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Abstract: Chronic hepatitis C virus (HCV) infection impacts approximately 71 million people 
and approximately 400,000 deaths are attributed to HCV-related liver disease annually worldwide. 
Mainstay of treatment for over 25 years has been pegylated interferon until the advent of protease 
inhibitors, which has led to all-oral HCV treatment regimens that have changed the outlook of 
hepatitis C treatment. Grazoprevir/elbasvir provides high rates of efficacy and tolerability and 
is an all-oral once daily treatment option for HCV infection. Efficacy of grazoprevir/elbasvir 
has been proven in patients with cirrhosis, patients who have previously failed treatment with 
peginterferon and ribavirin (RBV), patients with end-stage renal disease and patients with HIV 
co-infection. Data have shown a high barrier to resistance despite the presence of resistance-
associated substitutions. Grazoprevir/elbasvir represents a very promising regimen for treatment 
of HCV infection. This review provides a summary of pharmacology, efficacy, and safety of 
grazoprevir/elbasvir for the treatment of HCV infection.
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Introduction
For more than 25 years, pegylated interferon and ribavirin (PR) have been the mainstay 
of treatment for hepatitis C virus (HCV) infection until the recent advent of protease 
inhibitors.1–3 The emergence of protease inhibitor therapies in 2011 transformed the 
landscape of HCV treatment. However, there have been major limitations with initial 
direct-acting antiviral (DAA) agents including low genetic barrier to resistance, side 
effects, and significant drug-drug interactions.4–6
Grazoprevir is a second-generation NS3/4a protease inhibitor that demonstrates 
activity against resistance-associated substitutions (RAS) seen after failed therapy 
with first-generation protease inhibitors.7–12 Elbasvir is a NS5A replication complex 
inhibitor. Grazoprevir-Elbasvir has been approved by Food and Drug Administration 
(FDA) since 2016 for the treatment of HCV genotype 1 and 4 and with ribavirin in 
select patient populations. It has also been studied in patients with advanced chronic 
kidney disease (CKD). The purpose of this review is to summarize pharmacology, 
efficacy, and safety of grazoprevir-elbasvir.
Pharmacology
Grazoprevir is a synthetically derived quinoline-based p2-p4 macrocyclic derivative 
that is a strong inhibitor of HCV NS3/4A protease.13 NS3/4A protease is responsible 
for cleaving the long polyprotein produced from hepatitis C viral RNA template into 
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single proteins. This is an essential process for HCV RNA 
replication, which is inhibited by grazoprevir. The HCV 
NS5A is a critical RNA binding protein associated with per-
forming necessary functions for viral replication and virion 
assembly. Elbasvir directly inhibits the activity of NS5A 
protein within the HCV.
Pharmacokinetics and metabolism
Initial studies to evaluate pharmacokinetics of grazoprevir 
were performed in rats, dogs, and simian models.14–16 Oral (5 
mg/kg of body weight in rats and 1 mg/kg of body weight in 
dogs) and intravenous (bolus dose of 2 mg/kg of body weight 
in rats and 0.5 mg/kg of body weight in dogs) formulations 
were utilized in the studies.
The safety and pharmacokinetics of grazoprevir were 
evaluated by Brainard et al in healthy males after single-dose 
and multiple-dose administration.17 An oral dose of 2–1,600 
mg or placebo in fed or fasted state was administered to 
24 healthy males in the single dose group. An oral dose of 
100–1,000 mg or placebo once daily for 10 days was admin-
istered in 40 healthy males in the multiple-dose group. No 
serious adverse events occurred in the study, with one subject 
experiencing flu-like illness unrelated to the drug. Following 
single administration of an oral dose, the pharmacokinetic 
data revealed Tmax values of 2–5 hours and a terminal half-
life of 15–34.4 hours. Pharmacokinetics was not affected by 
administration of the medication with a high-fat meal. Dose 
proportional increases in mean area under the curve (AUC), 
Cmax, and 24 hour concentration values were seen up to 200 
mg. These values were much higher and did not increase 
in a dose proportional manner in doses greater than 200 mg. 
Steady state was obtained after six doses, and approximately 
three-fold increase in AUC and Cmax was noted for grazo-
previr doses of 100–400 mg. Only 1.5-fold increase in AUC 
and Cmax was observed at doses higher than 400 mg.
Mean AUC and Cmax increased in a greater than dose 
proportional manner at steady state in the multiple-dose group 
with median Tmax of 2.5–4 hours and half-life of 20 hours. 
The single-dose and multiple-dose groups demonstrated 
consistent pharmacokinetic data. Pharmacokinetic data were 
evaluated in six patients with HCV in another study, one with 
genotype 1 and five with genotype 3, which yielded higher 
drug exposure as compared to healthy controls (1.2–2.1 fold).18
A non-randomized, open-label Phase II study (C-SALT 
trial) assessed the efficacy, safety, and pharmacokinetics of 
grazoprevir plus elbasvir in patients with HCV genotype 1, 4, 
or 6 infection and Child-Pugh-B (CP-B) cirrhosis.19 Pharma-
cokinetics of 30 patients with HCV genotype 1 infection and 
CP-B cirrhosis who received grazoprevir 50 mg and elbasvir 
50 mg as separate entities was compared to that of 10 non-
cirrhotic patients with HCV genotype 1 who received grazo-
previr 100 mg/elbasvir 50 mg combination product. Plasma 
samples over 24 hours at treatment week 4 were collected in 
a subset of CP-B and non-cirrhotic patients. Results of the 
study demonstrated the exposure of elbasvir was similar in 
both groups but grazoprevir exposure was higher in CP-B 
cirrhotic patients compared to non-cirrhotic patients.
Clinical efficacy
In a randomized active-control trial, Manns et al evaluated the 
safety and efficacy of PR combined with either grazoprevir 
or boceprevir.20 Treatment-naïve patients with genotype 1 
infection and HCV RNA level ≥104 IU/mL at screening were 
eligible. The study randomized 332 treatment-naïve genotype 
1 patients (60% with genotype 1a) to receive either boceprevir 
+ PR at standard doses (control) or grazoprevir 100, 200, 400, 
or 800 mg daily + PR for 12 weeks. Patients received an addi-
tional 12 weeks of PR alone if they achieved rapid virologic 
response (RVR), defined as HCV RNA not detected at week 
4 of treatment, or 36 weeks of PR if RVR was not achieved. 
The study demonstrated higher sustained virologic response 
(SVR) rate at the 24-week follow-up (SVR
24
) in the grazoprevir 
group (86%–93%) compared to the boceprevir group (61%).
Howe et al further explored the study to evaluate six 
patients with virologic failure.21 The substitutions associ-
ated with clinical resistance to other protease inhibitors 
were present in 73 of 261 (28%) patients in the grazoprevir 
group at study enrollment. SVR
24
 was observed in 85% of 
these patients with genotype 1a and in 97% of the patients 
with genotype 1b despite the presence of variants. SVR
24 
was 
achieved in 59 of 66 patients (89%) in the 100 mg/day group.
Lagging and colleagues evaluated the efficacy of lower 
doses of grazoprevir in treatment naïve HCV genotype 1 
patients with HCV RNA level ≥10,000 IU/mL.22 Primary 
objective was SVR rate at 12 weeks after the end of treat-
ment (SVR
12
) for each group. Patients were randomized to 
receive grazoprevir 25 mg (n=29), 50 mg (n=28), or 100 mg 
(n=30) + PR for 12 weeks. Treatment with PR was extended 
by 12 weeks if HCV RNA was detectable at week 4. Of the 
87 patients enrolled, 80% were genotype 1a and 18% were 
African American. SVR
12
 was achieved in 54.2%, 84%, and 
88.5% of patients in grazoprevir 25 mg, 50 mg and 100 mg 
groups, respectively. Treatment failure occurred in 46%, 
16%, and 15% of patients in grazoprevir 25 mg, 50 mg, and 
100 mg groups, respectively. RAS were present in 38 of 87 
patients (44%) at baseline, all of which were susceptible 
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to grazoprevir. Type and frequency of adverse events were 
similar in all three groups.
C-WORTHY was a randomized, multi-center, open-label, 
Phase II trial that evaluated safety and efficacy of 8 weeks 
versus 12 weeks of treatment with grazoprevir and elbasvir 
with or without ribavirin in HCV genotype 1 mono-infected 
and HIV/HCV co-infected patients.23 Treatment-naïve 
patients with HCV RNA ≥10,000 IU/mL without cirrhosis 
were eligible to participate. HIV co-infected patients were 
required to be well controlled with raltegravir plus two 
nucleoside or nucleotide reverse transcriptase inhibitors for 
at least 8 weeks prior to enrollment and have undetectable 
HIV RNA for at least 24 weeks with CD4 count of 300 cells/
mL or higher. Table 1 describes randomization of patients in 
eight study arms. Patients’ bodyweight was utilized for riba-
virin dosing (800–1,400 mg/day). The primary objective was 
to assess SVR
12
 for each group. The majority of the patients 
enrolled in the study were White (88%) males (59%) with 
median age of 52 years. Baseline HCV RNA was >2,000,000 
IU/mL in 56% of the patients and 72% had HCV genotype 1a 
infection. In the co-infected patients, there were more males 
(80%) with younger age (mean 47 years) and higher baseline 
HCV RNA count. SVR
12
 was achieved in 93% with ribavirin 
and 98% without ribavirin treatment in the mono-infected 
patients treated for 12 weeks. In the co-infected patients, the 
SVR
12
 rate was 97% with ribavirin and 87% without ribavi-
rin. No significant differences were noted in SVR
12
 rates for 
mono-infected and co-infected patients, for regimens with 
or without ribavirin, and dose of elbasvir. The SVR
12
 rates 
were lower in HCV genotype 1a patients receiving treatment 
for 8 weeks (80%) compared to 12 weeks (95%). Virologic 
failure occurred in 12 patients in the study, 10 patients with 
genotype 1a and two with genotype 1b.
The C-WORTHY part B study enrolled patients with 
genotype 1, treatment naïve, with cirrhosis (cohort 1) and 
patients who previously failed treatment with PR, with or 
without cirrhosis (cohort 2).24 Patients were randomized to 
receive grazoprevir 100 mg/elbasvir 50 mg with or without 
ribavirin for 12 or 18 weeks. Patients were randomized in 
eight treatment groups as described in Table 2. Median age of 
the patients in the study was 56 years with most having cir-
rhosis (67%); 58% were males, and 92% were White. Patients 
in cohort 1 achieved SVR
12
 rates of 90%–97% with no sig-
nificant benefit of extended treatment duration. One patient 
in cohort 1 had virologic breakthrough and five patients had 
virologic relapse. Patients in cohort 2 achieved SVR
12
 rates 
of 91%–100%, which was similar to treatment-naïve patients 
with cirrhosis. One patient had virologic breakthrough and 
three patients had virologic relapse. A subgroup analysis to 
assess the impact of ribavirin showed it did not contribute 
to additional efficacy in patients with cirrhosis, in patients 
who have previously failed PR therapy, and patients with 
high viral loads (>10,000,000 IU/mL).
C-WORTHY part D study compared the efficacy of 
grazoprevir 100 mg/elbasvir 50 mg with ribavirin therapy in 
HCV genotype 3 patients for 12 weeks versus 18 weeks.25 
This was an open-label study with patients randomized in 
1:1 fashion with primary endpoint of SVR
12
. A total of 21 
patients were included in the 12-week (W12) group and 20 
patients in the 18-week (W18) group. SVR
12 
rate of 45% was 
achieved in W12 group and 57.1% in W18 group. Break-
through viremia occurred in six patients in W12 group and 
five patients in W18 group; none of the patients experienced 
relapse. There were 35 patients with baseline NS3 RAS and 
18 (51%) achieved SVR
12
. Seven out of 17 patients (41%) in 
W12 group and 11 out of 18 (61%) in W18 group achieved 
SVR
12. 
There were seven patients with baseline NS5A RAS 
and three (43%) achieved SVR
12
. Two of five patients (40%) 
in W12 group and one of two patients (50%) in W18 group 
achieved SVR
12
.
Table 1 C-wORTHY – study treatment groups
Treatment 
arm
Number of 
patients*
Infection HCV 
genotype
Treatment Duration SVR12
1 25 Mono-infected 1a + 1b Grazoprevir 100 mg + elbasvir 20 mg + ribavirin 12 weeks 93%
2 27 Mono-infected 1a + 1b Grazoprevir 100 mg + elbasvir 50 mg + ribavirin 12 weeks 93%
3 13 Mono-infected 1b Grazoprevir 100 mg + elbasvir 50 mg 12 weeks 98%
4 30 Mono-infected 1a Grazoprevir 100 mg + elbasvir 50 mg + ribavirin 8 weeks 80%
5 33 Mono-infected 1a + 1b Grazoprevir 100 mg + elbasvir 50 mg + ribavirin 12 weeks 93%
6 31 Mono-infected 1a Grazoprevir 100 mg + elbasvir 50 mg 12 weeks 98%
7 29 Co-infected 1a + 1b Grazoprevir 100 mg + elbasvir 50 mg + ribavirin 12 weeks 97%
8 30 Co-infected 1a + 1b Grazoprevir 100 mg + elbasvir 50 mg 12 weeks 87%
Notes: *Treatment-naïve and non-cirrhotic patients. Data from Sulkowski et al.23
Abbreviations: HCv, hepatitis C virus; SvR12, sustained virologic response 12 weeks after treatment completion
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C-EDGE-TN was a Phase III study that evaluated the effi-
cacy and safety of grazoprevir/elbasvir fixed-dose combina-
tion regimen without interferon or ribavirin in treatment-naïve 
patients mono-infected with HCV genotypes 1, 4, or 6 with or 
without cirrhosis.26 Patients received a fixed-dose combination 
of grazoprevir 100 mg/elbasvir 50 mg at the start of  the study 
(immediate-treatment group) or placebo (deferred treatment 
group) for 16 weeks following which they received treatment 
in an open-label manner. The study aimed to enroll 20% of 
patients with cirrhosis and 15% with genotype 4 or genotype 
6 infection. A total of 421 patients were enrolled, of whom 
54% were male, 63% White, 6% with genotype 4, 3% with 
genotype 6, and 91% genotype 1, and 22% of the patients 
had cirrhosis. The SVR
12
 rates were 92% in patients with 
genotype 1 infection, 100% in genotype 4 infection, and 80% 
in genotype 6 infection. SVR
12
 rates between cirrhotic and 
non-cirrhotic patients were similar; 97% vs 94% respectively. 
Virologic failure was seen in 13 patients (11 with genotype 1 
and two with genotype 6 infection).
The C-EDGE Co-Infection study was a Phase II study 
evaluating 218 patients with hepatitis C genotype 1, 4, or 6 
and HIV.27 Patients were treated with a combination therapy of 
grazoprevir 100 mg/elbasvir 50 mg once daily for 12 weeks. 
Patients were eligible to enroll if they were on antiretroviral 
therapy for at least 8 weeks with an undetectable HIV RNA 
level, and CD4 count greater than 200 cells/mm3 or HIV 
treatment-naïve patients with CD4 count greater than 500 
cells/mm3 and an HIV RNA level less than 50,000 copies/
mL. SVR
12 
was attained in 210 patients (96%) and all 35 
patients with cirrhosis achieved SVR
12
.
C-SALVAGE was a Phase II study that evaluated the 
safety and efficacy of 12 weeks of grazoprevir 100 mg/elbas-
vir 50 mg daily in patients with prior treatment failure with a 
regimen containing a protease inhibitor such as boceprevir, 
telaprevir, or simeprevir.28 The study included patients with 
or without cirrhosis. SVR
24 
rates were high at 96.2% in 
spite of prior exposure and presence of NS3 substitutions. 
Ninety two percent (33/36) of patients with baseline NS3 or 
NS5A resistance and 94% (32/34) of patients with cirrhosis 
achieved SVR
24.
The C-SURFER was a randomized, parallel-group, 
placebo-controlled study that evaluated efficacy and safety of 
grazoprevir 100 mg/elbasvir 50 mg in patients with advanced 
(stage 4–5) CKD infected with HCV genotype 1.29 This study 
included patients who had failed pegylated interferon therapy 
and treatment-naïve patients with or without cirrhosis. Of the 
122 patients who received treatment in the immediate group, 
80% were treatment naïve, 6% had cirrhosis, and 52% were 
genotype 1a. The study comprised 18% of patients with 
stage 4 and 82% of patients with stage 5 CKD, with 76% on 
hemodialysis. SVR
12 
was 99% in the immediate group and 
98% in the deferred treatment group. SVR
12
 was achieved 
by 11 (84·6%) of 13 patients with detectable baseline NS5A 
RAS and 100% of patients with genotype 1a infection.
The C-SALT trial was a non-randomized, open-label 
Phase II study that assessed the efficacy, safety, and phar-
macokinetics of grazoprevir plus elbasvir in patients with 
HCV genotype 1, 4, or 6 infection and CP-B cirrhosis.19 The 
study enrolled 30 patients with HCV genotype 1 infection 
and CP-B cirrhosis who received grazoprevir 50 mg/elbasvir 
50 mg and 10 non-cirrhotic patients with HCV genotype 1 
who received grazoprevir 100 mg/elbasvir 50 mg in the phar-
macokinetics analyses group. All patients received treatment 
for 12 weeks. SVR
12 
was achieved in 90% of patients with 
CP-B cirrhosis and in 100% of non-cirrhotic patients. Relapse 
occurred in two patients in the CP-B cirrhosis arm and one 
patient died due to progression of liver disease versus none in 
the non-cirrhotic arm. At the 12-week follow-up, Child-Pugh 
score decreased in 18 patients and increased in four patients 
in the CP-B cirrhosis group.
C-EDGE CO-STAR was a Phase III study evaluat-
ing the efficacy and safety of grazoprevir and elbasvir in 
Table 2 C-wORTHY – Part B study treatment groups
Treatment 
arm
Number of 
patients
Treatment Duration SVR12
Previously untreated; 
with cirrhosis
1 31 Grazoprevir 100 mg/elbasvir 50 mg + ribavirin 12 weeks 90%
2 29 Grazoprevir 100 mg/elbasvir 50 mg 12 weeks 97%
3 32 Grazoprevir 100 mg/elbasvir 50 mg + ribavirin 18 weeks 97%
4 31 Grazoprevir 100 mg/elbasvir 50 mg 18 weeks 94%
PR-null, with or 
without cirrhosis
5 32 Grazoprevir 100 mg/elbasvir 50 mg + ribavirin 12 weeks 94%
6 33 Grazoprevir 100 mg/elbasvir 50 mg 12 weeks 91%
7 33 Grazoprevir 100 mg/elbasvir 50 mg + ribavirin 18 weeks 100%
8 32 Grazoprevir 100 mg/elbasvir 50 mg 18 weeks 97%
Note: Data from Lawitz et al.24
Abbreviations: SvR12, sustained virologic response 12 weeks after treatment completion; PR-null, previously untreated with Peg-interferon and Ribavirin.
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 treatment-naïve, HCV genotype 1, 4, or 6 infected patients 
receiving opioid agonist therapy for at least 3 months.30 This 
was a double blind, placebo-controlled, parallel-group study 
in which patients were randomized in a 2:1 fashion to an 
immediate treatment group (ITG) or a deferred treatment 
group (DTG). The ITG group received grazoprevir/elbasvir for 
12 weeks and the DTG group received placebo for 12 weeks, 
followed by 12 weeks of open-label grazoprevir/elbasvir. 
Patients were allowed to use non-prescribed drugs, which 
were monitored by urine drug screens. Of the 301 patients 
randomized, 76% had genotype 1a, 15% had genotype 1b, 
6% had genotype 4, 5% had genotype 6, 20% had cirrhosis, 
and 7% had HIV. At baseline, 79% were receiving methadone 
and 21% were receiving buprenorphine. A positive urine drug 
screen was present in 59% of patients for at least one of the 
following eight drug classes: amphetamines, barbiturates, ben-
zodiazepines, cannabinoids, cocaine, opiates, phencyclidine, 
and propoxyphene. Cocaine positivity was present in 10% of 
the patients, and opiate positivity was present in 25% of the 
patients. The modified data showed an SVR
12
 rate of 95% 
overall. Five patients were successfully treated but had viro-
logic failure with a different genotype, subtype, or viral strain.
Asselah et al evaluated 103 HCV genotype 4 infected 
patients.31 They analyzed 66 treatment-naïve (TN) patients 
and 37 treatment-experienced (TE) patients, including 17 
cirrhotic patients. Overall, 97% of the TN (6/6 cirrhotic 
patients) and 86% of the TE genotype 4 patients achieved 
SVR
12
. Among TE patients, 9/9 prior relapsers and 23/28 
prior on treatment failures achieved SVR
12
. Among TE cir-
rhotic patients, 77%, including 3/3 prior relapsers and 4/4 
treated with grazoprevir/elbasvir and ribavirin for 16 weeks, 
achieved SVR
12
. Longer duration of treatment and use of 
ribavirin increased the response rate in patients with prior 
on therapy failure.
Additional pertinent studies evaluating the use of grazo-
previr/elbasvir therapy in various patient populations are 
described in Table 3.32–35
Safety and tolerability
Various studies have demonstrated favorable safety and tol-
erability profile for grazoprevir. Transient and mild adverse 
events were reported in an initial phase I study utilizing 
grazoprevir doses from 50 mg to 800 mg daily for a week in 
84 HCV genotype 1 and three non-cirrhotic patients.18 In a 
randomized, active-controlled trial, Manns et al evaluated the 
safety and efficacy of PR combined with either grazoprevir 
or boceprevir.20 Patients received grazoprevir 100 mg, 200 
mg, 400 mg, or 800 mg daily with standard dose PR, or 
boceprevir with PR at standard doses. Safety was evaluated 
in 332 patients and the rate of serious adverse events was 
Table 3 Additional studies evaluating use of grazoprevir/elbasvir for treatment of HCv
Study Study design Treatment Genotype Patient population SVR
Brown et al32 Randomized, 
open-label, Phase ii
Genotype 2: GZR 100 
mg + RBv ± EBR 50 mg 
for 12 weeks; genotype 
4, 5 or 6: randomized to 
GZR/EBR ± RBv for 12 
weeks.
2, 4, 5, or 6 Treatment naïve, non-
cirrhotic patients
Genotype 2: SvR12 of 80% in GZR/EBR + 
RBv and 73% in GZR + RBv.
Genotype 4: SvR12 of 90% in GZR/EBR 
and 100% in GZR/EBR + RBv. Genotype 
5: SvR12 of 25% in GZR/EBR vs 100% in 
GZR/EBR + RBv. Genotype 6: SvR12 of 
75% in both groups
Hezode 
et al33
Randomized, 
placebo-
controlled, Phase 
iii study
12 weeks of GZR/EBR 
100 mg/50 mg in iTG vs 
DTG
1, 4, or 6 159 patients with 
HCv and sickle cell 
anemia, thalassemia, 
or hemophilia A/B 
or von willebrand 
disease
SvR12 of 93.5% in the iTG. SvR12 was 
achieved in 94.7%, 97.6%, and 89.4% 
of patients with sickle cell disease, 
b-thalassemia, and hemophilia A/B or von 
willebrand disease, respectively
Kwo et al34 Randomized, 
open-label, Phase 
iii study
12 vs 16 weeks of 
treatment with GZR/ 
EBR 100 mg/50 mg ± RBv
1,4, or 6 420 patients included: 
35% with cirrhosis, 
64% with null or 
partial response to PR 
treatment.
12 weeks of treatment: SvR12 of 92% in 
GZR/EBR vs SvR12 of 94% in GZR/EBR + 
RBv
16 weeks of treatment: SvR12 of 92% in 
GZR/EBR vs 98% in GZR/EBR + RBv
Sperl et al35 Randomized, 
open-label, Phase 
iii study
12 weeks of GZR/EBR 
100 mg/50 mg (n=129) 
vs sofosbuvir 400 mg + 
PR (n=128)
1 or 4 83% non-cirrhotic, 
75% treatment naïve, 
82% genotype 1b
SvR12 of 99% in GZR/EBR group and 90% 
in sofosbuvir/PR group
Abbreviations: DTG, deferred treatment group; EBR, elbasvir; GZR, grazoprevir; HCv, hepatitis C virus; iTG, immediate treatment group; RBv, ribavirin; SvR12, sustained 
virologic response 12 weeks after treatment completion; PR, Peg-interferon + ribavirin.
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similar in both groups (9% in grazoprevir group and 8% 
boceprevir group). The rate of adverse events leading to 
discontinuation of therapy was 7% in the grazoprevir group 
and 14% in the boceprevir group. Transaminase levels were 
increased significantly in patients receiving 400 mg and 
800 mg doses of grazoprevir. The grazoprevir dose in these 
patients was decreased to 100 mg and transaminase levels 
normalized by week 16.
Safety of grazoprevir was evaluated in 87 treatment-naïve, 
non-cirrhotic, genotype one patients by Lagging et al.22 Adverse 
events were similar in all the three groups. One patient in this 
study experienced myositis with transaminase levels >3× the 
upper limit of normal (ULN), total bilirubin >2× ULN, and 
CPK level of 1,032 U/L after 7 days of grazoprevir 100 mg. 
The patient required discontinuation of therapy leading to 
normalization of laboratory values.
The C-WORTHY study conducted by Sulkowski et al 
reported common adverse events to be mild to moderate 
fatigue, headache, nausea, and diarrhea.23 Overall, adverse 
events occurred in 56% of the patients with three patients 
reporting serious adverse events. Serious adverse events 
consisted of one case of nausea, one of asthenia related to 
the study drug, and one of staphylococcal infection, which 
was determined to be unrelated to the study drug. Ribavirin 
containing regimens had higher rates of adverse events, 
bilirubin elevation, or hemoglobin decrease. Transaminase 
elevations were not seen after 4 weeks of therapy.
Lawitz et al reported common adverse events of fatigue, 
headache, and asthenia of mild to moderate intensity.24 
 Serious adverse events were reported in seven patients, but 
only one patient had abdominal pain which was thought to 
be due to the study medication. One patient experienced 
transaminase increase, which resolved without interruption 
of therapy. Once again the rate of adverse events, bilirubin 
elevation, and hemoglobin decrease was higher in groups 
receiving ribavirin.
Most common adverse events reported in the  C-WORTHY 
part D study included headache, upper respiratory tract infec-
tion, and nausea.25 One patient discontinued therapy due to 
experiencing dyspnea, fatigue, and asthenia 2–3 days after 
starting treatment in the W18 group. C-EDGE-TN study also 
reported common adverse events of headache, fatigue, and 
nausea.26 There were nine serious adverse events reported, 
none of which were attributed to the study drug. Two patients 
discontinued study medication due to elevated aminotrans-
ferase levels and one patient due to palpitations and anxiety. 
In the C-EDGE Co-Infection study, the most common side 
effects were fatigue (13%), headache (12%), and nausea (9%) 
with no discontinuation due to adverse events.27 Two patients 
had transient HIV viremia.
Both groups in the C-SALT study experienced common 
adverse events of fatigue, arthralgia, nausea, and headache.19 
Four serious adverse events were reported in the CP-B cir-
rhosis group, none of which were attributed to the study drug. 
Transient bilirubin elevation without AST/ALT elevation was 
noted in four patients and one patient died due to progression 
of liver disease in the CP-B cirrhosis group.
In the C-EDGE CO-STAR study, occurrence of adverse 
events reported was similar in both groups with most com-
mon adverse events being fatigue, headache, nausea, and 
diarrhea.30 Serious adverse events were reported in 7% of the 
ITG and 4% of the DTG. One death occurred in the DTG 
group while on placebo.
Dusheiko et al conducted a safety analysis of grazopre-
vir/elbasvir from the results of studies published in which 
the therapy was given for 8, 12, 16, or 18 weeks.36 Adverse 
events and laboratory abnormalities reported on therapy or 
within 14 days of end of treatment were evaluated. A total 
of 1,795 patients were included in the evaluation: 1,033 
received grazoprevir/elbasvir without ribavirin, 657 received 
grazoprevir/elbasvir with ribavirin, and 105 received placebo. 
Of the patients enrolled, 61% were male, 13% were Black, 
27% had compensated cirrhosis, and 18% were HIV/HCV 
co-infected. The safety profile of grazoprevir/elbasvir without 
ribavirin was similar to placebo but the addition of ribavirin 
was associated with more adverse events. The most com-
monly reported adverse events were headache and fatigue in 
the patients receiving grazoprevir/elbasvir with or without 
ribavirin. There were three deaths among patients receiving 
grazoprevir/elbasvir that were unrelated to the study medica-
tion, while no patients in the placebo group died. Sex, age, 
presence of cirrhosis, and HIV/HCV co-infection were not 
associated with adverse events. ALT elevations of >5× the 
ULN at or after treatment week 8 occurred in 0.8% of the 
patients with normal ALT values at baseline. The ALT eleva-
tions were asymptomatic and the values normalized in the 
majority of the cases without any intervention.
Resistance-associated substitution
Development of RAS occurs due to the combination of high 
replication rate (1012 virions/day) of HCV and viral replica-
tion prone to errors. RAS testing is generally performed at 
baseline and at the time of virologic failure. NS3 and NS5A 
genes are amplified with a reverse transcription polymerase 
chain reaction and population sequencing.28 Response to 
suppression of these sequences is compared to wild-type 
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HCV sequencing for reference and categorized as low- or 
high-level resistance. Decreased efficacy of antiviral drugs is 
attributed to the continuous production of the RAS. Known 
variants associated with resistance to protease inhibitors 
include Q41R, F43S, R155K, V36M, T54S/A, and D168. 
Grazoprevir and elbasvir in vitro studies have shown no cross-
resistance among them as these agents are active against one 
another’s RAS.37 Manns et al obtained baseline RAS in 261 
of 264 patients.20 They identified 73 patients (28%) who had 
the presence of RAS to at least one other protease inhibitor. 
Of the 73 patients, 96% achieved SVR
24
 and six patients 
experienced virologic treatment failure. Howe et al further 
analyzed virologic resistance among the six patients.21 To 
assess genotypic variation at baseline or at virologic failure, 
the NS3/4A gene was amplified from samples with RNA 
levels ≥1,000 IU/mL using reverse transcription polymerase 
chain reaction followed by population and selective clonal 
sequences. Resultant amino acid sequences were compared 
to wild-type HCV1a or 1b reference sequences. A single 
NS3A protease amino acid substitution was considered 
clinically relevant. Five of the six patients with virologic 
treatment failure were in the 100 mg/day group. Four of the 
five patients were found to have low or undetectable trough 
plasma levels compared to the median levels in the pharma-
cokinetic substudy. One patient who experienced virologic 
treatment failure in the 200 mg/day group was infected with 
genotype 1b at the initiation of treatment, but had reinfection 
with genotype 3a after completion of treatment.
Sulkowski et al assessed the presence of RAS in patients 
receiving grazoprevir/elbasvir treatment.23 Seventy-five 
patients out of 216 (35%) had the presence of NS3 RAS at 
baseline; 68 patients (91%) achieved SVR
12
. At baseline, 25 
patients (12%) had the presence of NS5A RAS known to 
have more than five-fold resistance to elbasvir or other NS5A 
inhibitors. Seventeen of the 25 patients (68%) achieved SVR
12
.
Lawitz et al assessed the presence of RAS at baseline and 
at treatment failure.24 At baseline, NS3 RAS were present in 
79 of 248 patients (32%) and SVR
12
 was achieved in 73 of 79 
patients (92%). NS5A RAS were present in 34 of 243 patients 
(14%) at baseline, of whom 28 achieved SVR
12
 (82%). Ten 
patients had virologic treatment failure. Eight of 10 patients 
had detectable NS3 or NS5A RAS present. Common RAS 
detected in these patients included NS3:Y56H, A156T/G/V, 
D168A/Y, NS5A:M28T, Q30L/R, L31M, and Y93H/N. 
Based on the results of these studies, cross-resistance of many 
RAS, selected by other protease inhibitors, to grazoprevir/
elbasvir, seems to be absent. In patients with prior exposure to 
protease inhibitors, C-SALVAGE demonstrated rare potential 
for transient NS3 RAS as well as rare NS5A RAS persisting 
over the 24-week follow-up.28 Due to concerns with RAS 
leading to virologic failures, baseline polymorphism testing 
should be done prior to initiation of grazoprevir/elbasvir and 
duration of therapy should be adjusted accordingly.38
Drug interactions
Both grazoprevir and elbasvir are substrates of CYP3A4 and 
P-glycoprotein. Grazoprevir is also a substrate of the organic 
anion-transporting polypeptide (OATP). Co-administration 
of grazoprevir/elbasvir with OATP1B1/3 is contraindicated. 
Use of strong inducers of CYP3A4 is contraindicated while 
on grazoprevir/elbasvir, and use of moderate CYP3A4 induc-
ers or inhibitors is not recommended while on grazoprevir/
elbasvir therapy. Grazoprevir/elbasvir use in combination 
with statins should be used cautiously as exposure to statins 
is increased. Drug-drug interactions with grazoprevir and 
elbasvir are summarized in Tables 4 and 5.38
Conclusion
The grazoprevir/elbasvir regimen has significant advantages 
over first-generation direct-acting agents. It has a favorable 
pharmacokinetic profile with high liver concentration that 
allows for once-daily dosing with a single tablet. Grazopre-
vir/elbasvir demonstrates a high barrier to resistance with 
activity against substitutions known to have resistance to 
first-generation protease inhibitors.37 It demonstrates high 
SVR rates among HCV genotype 1 and 4 treatment-naïve 
and treatment-experienced patients, including compensated 
cirrhotics, without necessity of interferon injection. In addi-
tion, it presents an option for therapy without the need for 
Table 4 Use of medications contraindicated with grazoprevir/
elbasvir38
Contraindicated medications that cause decreases in grazoprevir and 
elbasvir plasma concentrations due to CYP3A induction, leading to loss 
of virologic response:
• Phenytoin
• Carbamazepine
• Rifampin
• St. John’s wort (Hypericum perforatum)
• Efavirenz
Contraindicated medications that cause significant increase in 
grazoprevir plasma concentrations due to OATP1B1/3 inhibition which 
may lead to ALT elevations:
• Atazanavir
• Darunavir
• Lopinavir
• Saquinavir
• Tipranavir
• Cyclosporine
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ribavirin in genotype 1 patients. Further data are needed 
on the potential for use of this medication in patients with 
decompensated cirrhosis.
Grazoprevir/elbasvir has also demonstrated efficacy 
among HCV/HIV co-infected patients with SVR
12
 rates 
greater than 95% in HCV genotype 1, 4, and 6 patients.27 
These data suggest that the efficacy of grazoprevir/elbasvir 
is similar in mono-infected and co-infected patients. Since 
grazoprevir is a mild CYP3A4 inhibitor, there are clinically 
important drug-drug interactions that should be thoroughly 
evaluated when it is utilized concomitantly with anti-retroviral 
therapy. Grazoprevir/elbasvir does not have an interaction with 
pantoprazole or famotidine, thus making this regimen more 
attractive for patients who take these agents, as other HCV 
DAA regimens require separation of acid reducing agents.
There has been an unmet medical need to treat HCV infec-
tion in patients with CKD and those on hemodialysis. Clinical 
trials with grazoprevir/elbasvir in CKD demonstrate extremely 
promising efficacy and tolerability.29 With an aging HCV 
population and expected increased incidence of renal impair-
ment in this cohort, the grazoprevir/elbasvir regimen seems 
particularly attractive, representing the first oral ribavirin- free 
regimen to be evaluated in this patient population.
Current data demonstrate the combination of grazopre-
vir/elbasvir to be a very efficacious regimen representing a 
strong protease inhibitor/NS5A inhibitor oral, single-tablet 
regimen for treatment of HCV infection in patients with 
compensated cirrhosis, HCV/HIV co-infection and with 
CKD. Additionally, it represents a medication that maintains 
safety and efficacy regardless of the severity of fibrosis. A 
high degree of all-oral efficacy was maintained even among 
patients with prior exposure to earlier generation protease 
inhibitors.28 This regimen is safe and effective and is well 
tolerated among HCV patients with narcotic and opioid 
dependence including methadone and cocaine.30 The robust 
data among the general genotype 1 and 4 population provide 
another option for a field in need of a viable competitive 
market, for which cost of therapy is the limiting factor. These 
data include patients with cirrhosis, treatment experience, 
HIV co-infection, exposure to protease inhibitors and those 
on dialysis – potentially expanding the utility of this regimen 
in a broad arena of patients.
Disclosure
The authors report no conflicts of interest in this work.
References
1. World Health Organization. (2017). Hepatitis C (Fact sheet No. 164). 
Web. October 2017. Available from: http://www.who.int/mediacentre/
factsheets/fs164/en/>. Accessed November 15, 2017.
2. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality 
from 235 causes of death for 20 age groups in 1990 and 2010: a sys-
tematic analysis for the Global Burden of Disease Study 2010. Lancet. 
2012;380(9859):2095–2128.
3. Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association 
for the Study of Liver Diseases. Diagnosis, management, and treatment 
of hepatitis C: an update. Hepatology. 2009;49(4):1335–1374.
4. Kiser JJ, Flexner C. Direct-acting antiviral agents for hepatitis C virus 
infection. Annu Rev Pharmacol Toxicol. 2013;53:427–449.
5. Gentile I, Buonomo AR, Borgia F, Zappulo E, Castaldo G, Borgia 
G. MK-5172: a second-generation protease inhibitor for the treat-
ment of hepatitis C virus infection. Expert Opin Investig Drugs. 
2014;23(5):719–728.
6. Cornberg M, Manns MP. New kids on the block – step by step to an 
ideal HCV therapy. Lancet. 2015;385(9973):1050–1052.
Table 5 Drug-drug interactions of grazoprevir and elbasvir
Medication Effect on 
concentration
Comment
Nafcillin Decreases grazoprevir 
and elbasvir 
concentrations
Co-administration not 
recommended
Ketoconazole increases grazoprevir 
and elbasvir 
concentrations
Bosentan Decreases grazoprevir 
and elbasvir 
concentrations
Etravirine Decreases grazoprevir 
and elbasvir 
concentrations
Elvitegravir/
cobicistat/
emtricitabine/
tenofovir 
(disoproxil 
fumarate or 
alafenamide)
increases grazoprevir 
and elbasvir 
concentrations
Modafinil Decreases grazoprevir 
and elbasvir 
concentrations
Tacrolimus increased tacrolimus 
concentrations
Frequent monitoring of 
tacrolimus whole blood 
concentrations, renal 
function, and adverse 
events upon initiation 
of co-administration is 
recommended
Atorvastatin increases 
concentrations of 
statins
Do not exceed atorvastatin 
20 mg daily dose while on 
grazoprevir/elbasvir
Fluvastatin
Lovastatin
Simvastatin
Use lowest necessary statin 
dose and monitor closely 
for myopathy while on 
grazoprevir/elbasvir
Rosuvastatin Do not exceed rosuvastatin 
10 mg daily dose while on 
grazoprevir/elbasvir
Note: Data from Zepatier™ (elbasvir/grazoprevir) [package insert].38
Hepatic Medicine: Evidence and Research 2018:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
41
Grazoprevir/elbasvir for the treatment of adults with chronic hepatitis C
7. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, 
with or without ribavirin, to treat chronic infection with hepatitis C 
virus genotype 1 in non-responders to pegylated interferon and ribavirin 
and treatment-naive patients: the COSMOS randomised study. Lancet. 
2014;384(9956):1756–1765.
8. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al; AI444040 
Study Group. Daclatasvir plus sofosbuvir for previously treated or 
untreated chronic HCV infection. N Engl J Med. 2014;370(3):211–221.
9. Manns M, Pol S, Jacobson IM, et al; HALLMARK-DUAL Study 
Team. All-oral daclatasvir plus asunaprevir for hepatitis C virus 
genotype 1b: a multinational, phase 3, multicohort study. Lancet. 
2014;384(9954):1597–1605.
10. Afdhal N, Zeuzem S, Kwo P, et al; ION-1 Investigators. Ledipasvir 
and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 
2014;370(20):1889–1898.
11. Afdhal N, Reddy KR, Nelson DR, et al; ION-2 Investigators. Ledipasvir 
and sofosbuvir for previously treated HCV genotype 1 infection. N Engl 
J Med. 2014;370(16):1483–1493.
12. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with 
ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 
2014;370(17):1594–1603.
13. Shah U, Jayne C, Chackalamannil S, et al. Novel quinoline-based P2-P4 
macrocyclic detivatives as pan-genotypic HCV NS3/4a protease inhibi-
tors. ACS Med Chem Lett. 2014;5(3):264–269.
14. Petry AS, Fraser IP, O’Mara E, et al. Safety and antiviral activity of 
MK-5172, a next generation HCV N53/4A protease inhibitor with a 
broad HCV genotypic activity spectrum and potent activity against 
known resistance mutants, in genotype 1 and 3 HCV-infected patients. 
Hepatology. 2011;54(4):531A♥.
15. Summa V, Ludmerer SW, McCauley JA, et al. MK-5172, a selective 
inhibitor of hepatitis C Virus NS3/4a protease with broad activity 
across genotypes and resistant variants. Antimicrob Agents Chemother. 
2014;56(8):4161–4167.
16. Coburn CA, Meinke PT, Chang W, et al. Discovery of MK-8742: an 
HCV NS5A inhibitor with broad genotype activity. ChemMedChem. 
2013;8(12):1930–1940.
17. Brainard DM, Petry A, Anderson MS, et al. Safety, tolerability, and phar-
macokinetics after single and multiple doses of MK-5172, a novel HCV 
NS3/4A protease inhibitor with potent activity against known resistance 
mutants, in healthy subjects. Hepatology. 2010;52:1216A–1217A.
18. Caro L, Anderson M, Du L, et al. Pharmacokinetics and pharmacoki-
netic/pharmacodynamic relationship for MK-5172, a novel hepatitis C 
virus (HCV) NS3/4A protease inhibitor, in genotype 1 and genotype 3 
HCV –infected patients. Hepatology. 2011;54(4):1005A.
19. Jacobson I, Poordad F, Firpi-Morell R, et al. Efficacy and safety of 
grazoprevir and elbasvir in hepatitis C genotype 1 infected patients 
with Child-Pugh class B cirrhosis (C-SALT). [EASL abstract O008]. 
J Hepatol. 2015;62(Suppl 2):S193–S194.
20. Manns M, Vierling JM, Bacon BR, et al. High sustained viral response 
at 12-and 24-week follow-up of MK-5172 with pegylated interferon 
alfa-2b and ribavirin (PR) in HCV genotype 1 treatment-naive non-
cirrhotic patients. J Hepatol. 2013;58:S30.
21. Howe AY, Black S, Curry S, et al. Virologic resistance analysis from a 
phase 2 study of MK-5172 combined with pegylated interferon/ribavirin 
in treatment-naive patients with hepatitis c virus genotype 1 infection. 
Clin Infect Dis. 2014;59(12):1657–1665.
22. Lagging M, Brown A, Mantry PS, et al. Grazoprevir plus peginterferon 
and ribavirin in treatment-naive patients with hepatitis C virus genotype 
1 infection: a randomized trial. J Viral Hepat. 2016;23(2):80–88.
23. Sulkowski M, Hezode C, Gerstoft J, et al. Efficacy and safety of 8 
weeks versus 12 weeks of treatment with grazoprevir (MK-5172) 
and elbasvir (MK-8742) with or without ribavirin in patients with 
hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus 
co-infection (C-WORTHY): a randomised, open-label phase 2 trial. 
Lancet. 2015;385(9973):1087–1097.
24. Lawitz E, Gane E, Pearlman B, et al. Efficacy and safety of 12 weeks 
versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir 
(MK-8742) with or without ribavirin for hepatitis C virus genotype 1 
infection in previously untreated patients with cirrhosis and patients 
with previous null response with or without cirrhosis (C-WORTHY): 
a randomised, open-label phase 2 trial. Lancet. 2015;385(9973): 
1075–1086.
25. Gane E, Nahass R, Luketic V, et al. Efficacy of 12 or 18 weeks of 
grazoprevir plus elbasvir with ribavirin in treatment-naive, noncirrhotic 
HCV genotype 3-infected patients. [EASL abstract P0776]. J Hepatol. 
2015;62(Suppl 2):S621.
26. Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir–elbasvir combina-
tion therapy for treatment-naive cirrhotic and noncirrhotic patients with 
chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized 
trial. Ann Intern Med. 2015;163(1):1–13.
27. Rockstroh JK, Nelson M, Katlama C, et al. Efficacy and safety of 
grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with 
hepatitis C virus and HIV co-infection (C-EDGE CO-INFEC-
TION): a non-randomised, open-label trial. Lancet HIV. 2015;2(8): 
e319–e327.
28. Buti M, Gordon SC, Zuckerman E, et al. Grazoprevir, elbasvir, and 
ribavirin for chronic hepatitis C virus genotype 1 infection after failure 
of pegylated interferon and ribavirin with an earlier-generation protease 
inhibitor: final 24-week results from C-SALVAGE. Clin Infect Dis. 
2016;62(1):32–36.
29. Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treat-
ment-naive and treatment-experienced patients with hepatitis C virus gen-
otype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER 
study): a combination phase 3 study. Lancet. 2015;386(10003): 
1537–1545.
30. Dore G, Altice F, Litwin A, et al. C-EDGE CO-STAR: efficacy 
of grazoprevir and elbasvir in persons who inject drugs (PWID) 
receiving opioid agonist therapy. [AASLD abstract 40]. Hepatology. 
2015;63(Suppl 1):227A.
31. Asselah T, Reesink HW, Gerstoft J, et al. High efficacy of grazoprevir 
and elbasvir with or without ribavirin in 103 treatment-naive and 
experienced patients with HCV genotype 4 infection: a pooled analysis. 
[AASLD abstract 251]. Hepatology. 2015;63(Suppl 1):340A.
32. Brown A, Hézode C, Zuckerman E, et al; C-SCAPE Study Investigators. 
Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in 
participants with HCV genotype 2, 4, 5, or 6 infection: the C-SCAPE 
study. J Viral Hepat. Epub 2017 Nov 20.
33. Hézode C, Colombo M, Bourlière M, et al; C-EDGE IBLD Study 
Investigators. Elbasvir/grazoprevir for patients with hepatitis C virus 
infection and inherited blood disorders: a phase III study. Hepatology. 
2017;66(3):736–745.
34. Kwo P, Gane EJ, Peng CY, et al. Effectiveness of elbasvir and grazoprevir 
combination, with or without ribavirin, for treatment- experienced patients 
with chronic hepatitis C infection. Gastroenterology. 2017;152(1): 
164–175.e4
35. Sperl J, Horvath G, Halota W, et al. Efficacy and safety of elbasvir/
grazoprevir and sofosbuvir/pegylated interferon/ribavirin: a phase III 
randomized controlled trial. J Hepatol. 2016;65(6):1112–1119.
36. Dusheiko GM, Manns MP, Vierling JM, et al. Safety and tolerability of 
grazoprevir/elbasvir in patients with chronic hepatitis C (HCV) infec-
tion: integrated analysis of phase 2–3 trials. [AASLD abstract 712]. 
Hepatology. 2015;63(Suppl 1):562A.
37. Lahser F, Liu R, Bystol K et al. A combination containing MK-5172 
(HCV NS3 protease inhibitor) and MK-8742 (HCV NS5A inhibitor) 
demonstrates high barrier to resistance in HCV replicons. Hepatology. 
2012;56:236A.
38. Zepatier™ (elbasvir/grazoprevir) [package insert]. Whitehouse Station, 
NJ: Merck & Co., INC; 2016.
Hepatic Medicine: Evidence and Research 2018:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Hepatic Medicine: Evidence and Research
Publish your work in this journal
Submit your manuscript here: https://www.dovepress.com/hepatic-medicine-evidence-and-research-journal
Hepatic Medicine: Evidence and Research is an international, peer-
reviewed, open access journal covering all aspects of adult and pediatric 
hepatology in the clinic and laboratory including the following topics: 
Pathology, pathophysiology of hepatic disease; Investigation and treat-
ment of hepatic disease; Pharmacology of drugs used for the treatment 
of hepatic disease. Issues of patient safety and quality of care will also 
be considered. The manuscript management system is completely online 
and includes a very quick and fair peer-review system, which is all easy 
to use. Visit http://www.dovepress.com/testimonials.php to read real 
quotes from published authors.
Dovepress
42
Sulejmani and Jafri
